Broad Institute acquires license to all ChemAxon products and deploys across Chemical Biology Platform.
Compound registration, structure search and computed properties rolled out.
Budapest, Hungary and Cambridge, Massachusetts, 19 August 2010 – ChemAxon, a leading provider of chemistry software for life sciences, announced today that they have entered into an agreement with the Broad Institute of Harvard and MIT, which will license ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use. Broad will support their legacy small molecule registration system and other functionality across their Chemical Biology Platform with ChemAxon’s technology.
In addition to ChemAxon’s discovery and desktop tools, the Broad Institute has already updated their core technology for archiving small molecules by deploying the JChem platform toolkit within their existing system.
“This adoption is a part of our strategy to provide our scientists in the Chemical Biology Platform with the most modern and capable tools to accelerate our research,” said Michael Foley, Director of the Broad’s Chemical Biology Platform. “The extensive capabilities of the ChemAxon software support our ongoing efforts to build and apply state of the art facilities to support our work.”
The evaluation and deployment is to be presented during ChemAxon’s User Group Meeting being held in Boston’s Omni Parker House, September 14-15, the complete program is here: http://www.chemaxon.com/events/2010-us-ugm/
About ChemAxon
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit www.chemaxon.com.
BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine
| Ness Ziona, Israel – 17 August 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a universal influenza vaccine, today announced that it has received the approvals of the Ethics (“Helsinki”) Committees of the Institutional Review Boards (IRB) of both the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem (“Hadassah”) and the Tel Aviv Sourasky Medical Center (“Ichilov”), to perform a Phase II clinical trial to evaluate the safety and immunogenicity of BiondVax’s universal influenza vaccine candidate, the Multimeric-001.
Both Hadassah and Ichilov are internationally recognized medical facilities that have vast experience in the conduct of clinical trials. The principal investigators conducting the clinical trial will be Prof. Yoseph Caraco, Director of the Clinical Research Center at Hadassah and Dr. Jacob Atsmon, Director of the Clinical Research Center at Ichilov. The trial is designed to include a total of 160 participants, both male and female, 18-49 years old, who will be divided into three groups: a treatment group of 80 participants that will receive the 500mcg adjuvanted formulation of the Multimeric-001 vaccine, and two control groups of 40 participants each, that will receive adjuvanted and non-adjuvanted placebo formulations, respectively. Screening of the potential participants will commence immediately, with the first administrations of the vaccine expected to take place in October 2010. The Company expects to be able to report headline results from this trial by the end of the second quarter of 2011. Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientific Officer, said, “We are very pleased to have received the necessary approvals for the initiation of our first Phase II clinical trial. We are looking forward to commencing the trial in October, and to continuing our progress towards the successful development of the world’s first truly universal influenza vaccine.” |
|
| For further information, please contact: | |
| Danny Aronovic
Public Relations Consultant GKS Marketing |
Tel: +972-98995813
Mob: +972-507991121 |
| About BiondVax Pharmaceuticals Ltd. | |
| BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains and pandemic influenza strains, such as Swine flu and Avian flu.
BiondVax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. BiondVax has recently successfully concluded two Phase I/II clinical trials for the Multimeric-001 vaccine. The vaccine was shown to be safe and immunogenic in both trials. The first Phase II clinical trial is scheduled to commence in the second half of 2010. For further information on BiondVax, please visit www.biondvax.com |
|
Headwaters MB Adds to Life Sciences Team
Headwaters MB announced that Don Warriner and Brad Rosborough have joined the firm as Managing Directors within the Life Sciences practice.
Don Warriner joined Headwaters from Venture West Partners where he was focused on capital formation, sell-side and buy-side opportunities in software / technology companies. Don previously was an executive at IBM and the CEO at Data National Corp.
Brad Rosborough joined Headwaters from Three-Sixty Advisory Group, LLC where he was focused on strategy work with emerging healthcare companies. Brad has previously worked as an executive at several large organizations including Anthem Health, FHP International Corp. and Bio Cybernetics International.
“Don and Brad round out our Life Sciences practice with terrific transaction and operations experience with both emerging and large established companies in their space,” said Philip W. Seefried, the Co-Founder & CEO of Headwaters. “They complement our existing biotech practice and bring an expert-level focus to our clients.”
Drug inventor report profiles individuals, US states, and countries leading pharmaceutical innovation
A new report from DrugPatentWatch.com profiles the leading researchers, US states, and countries responsible for drugs approved over the past ten years.
The report features:
- Top Inventors
- Which inventors were granted the most patents?
- Patents per Inventor
- The patents awarded to each inventor
- Approved Drugs per Inventor
- The approved drugs protected by each inventor’s patents
- Co-Inventors per Inventor
- The co-inventors listed on each inventor’s patents
- Assignees per Inventor
- The assignees listed on each inventor’s patents
- Inventors per US State
- A count of the number of inventors in each state, along with the number of patents awarded to each inventor
- Inventors per Country
- A count of the number of inventors in each country, along with the number of patents awarded to each inventor
Here is a short list of the top drug inventors:
| Inventor | US State / Country | Number of Patents |
|---|---|---|
| Wong, Patrick S. | California | 24 |
| Theeuwes, Felix | California | 17 |
| Ebert, Charles D. | Utah | 17 |
| Chaudry, Imtiaz A. | New Jersey | 17 |
| Ayer, Atul D. | California | 16 |
| Mandeville, III, W. Harry | Massachusetts | 16 |
| Sequeira, Joel A. | New York | 15 |
| Ogawa, Yasuaki | Japan | 15 |
| Rand, Paul K. | United Kingdom | 15 |
For more information, see http://www.DrugPatentWatch.com/reports/ .
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments